4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-15-000055
$BHCCIK 0000885590operating
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 6:13 PM ET
Size
7.8 KB
Accession
0000885590-15-000055
Insider Transaction Report
Form 4
Rosiello Robert L.
EVP, Chief Financial Officer
Transactions
- Award
Restricted Share Units
2015-07-01+204,000→ 420,900 total - Award
Restricted Share Units
2015-07-01+204,000→ 216,900 total
Footnotes (4)
- [F1]This number represents the maximum number of performance-based Restricted Share Units ("PSUs") that can be paid out, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). See note (2).
- [F2]The PSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $230.82 (i.e., at 10% each vesting RSU earns one Common Share and at 30% each vesting RSU earns three Common Shares) on each of three measurement dates: 25% would vest on April 1, 2018, 50% on July 1, 2018 and 25% on October 1, 2018 with early vesting possible at higher TSR levels.
- [F3]This number represents the maximum number of performance-based Restricted Share Units ("PSUs") that can be paid out, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). See note (4).
- [F4]The PSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $230.82 (i.e., at 10% each vesting RSU earns one Common Share and at 30% each vesting RSU earns three Common Shares) on each of three measurement dates: 25% would vest on April 1, 2020, 50% on July 1, 2020 and 25% on October 1, 2020 with early vesting possible at higher TSR levels.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 6:13 PM ET
- Size
- 7.8 KB